|View printer-friendly version|
“Over the last several months, Kura has continued to deliver important advances against our pipeline priorities,” said
“In addition, we continue to evaluate tipifarnib in our ongoing Phase 2 trials in peripheral T-cell lymphoma (PTCL), myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), as well as advance our pipeline programs, KO-947 and KO-539, and we look forward to providing additional updates on these programs over the next several quarters. Finally, we expect the proceeds from our capital raise in August, coupled with our existing cash on hand, will provide the resources necessary to support our pipeline of precision medicines through a series of significant milestones anticipated in 2018.”
Recent Operational Highlights
- Positive Phase 2 study of tipifarnib in HRAS mutant HNSCC – In September, Kura announced positive topline results from a Phase 2 trial of tipifarnib in patients with HRAS mutant HNSCC. The trial achieved its primary endpoint prior to the completion of patient enrollment. Updated results from this study presented at the
AACR-NCI-EORTC International Conferencein October showed that confirmed partial responses were observed in four out of six patients with HRAS mutant HNSCC, and tipifarnib demonstrated rapid and durable responses, with partial responses observed beyond one year in duration.
- KO-539 shows robust anti-tumor activity in preclinical models of AML – In October, Kura presented preclinical data for KO-539, an inhibitor of the menin-MLL interaction, which supports the potential clinical utility of KO-539 in NPM1- and DNMT3A-mutant acute myeloid leukemia (AML). The data, presented at the
AACR-NCI-EORTC International Conference, suggest KO-539 drives robust and persistent responses in preclinical models of AML and has the potential to be active in subtypes representing approximately half of patients with AML.
- Completed follow-on offering – In August, Kura completed an underwritten public offering resulting in net proceeds to the company of approximately
Upcoming Potential Milestones and Expectations for Clinical Programs
- Presentation of preliminary results from the ongoing Phase 2 trial of tipifarnib in CMML at the
American Society of Hematology(ASH) Annual Meeting in December 2017
- Presentation on the CXCL12/CXCR4 Pathway as a potential target of tipifarnib in AML and MDS at ASH in
- Presentation on the CXCL12/CXCR4 Pathway as a potential target of tipifarnib from the ongoing Phase 2 trial of tipifarnib in PTCL at ASH in
- Presentation of updated results from the Phase 2 trial of tipifarnib in HRAS mutant HNSCC at the Multidisciplinary Head and Neck Cancers Symposium in
- Additional data from the Phase 2 trials of tipifarnib in PTCL, CMML and MDS in 2018
- Data from the KO-947 Phase 1 trial in non-hematological malignancies in 2018
- Initiation of a registration-enabling trial of tipifarnib in HRAS mutant HNSCC in 2018
Financial Results for the Third Quarter 2017
- Cash, cash equivalents and short-term investments totaled
$100.8 millionas of September 30, 2017, compared with $53.2 millionas of June 30, 2017. Cash, cash equivalents and short-term investments at the end of September includes net proceeds of approximately $53.5 millionfrom the follow-on offering in August. Management expects that current cash, cash equivalents and short-term investments will be sufficient to fund current operations into 2019.
- Research and development expenses for the third quarter of 2017 were
$7.1 million, compared to $5.3 millionfor the third quarter of 2016.
- General and administrative expenses for the third quarter of 2017 were
$2.4 million, compared to $1.7 millionfor the third quarter of 2016.
- Net loss for the third quarter of 2017 was
$9.3 million, or $0.38per share, compared to a net loss of $6.9 million, or $0.37per share, for the third quarter of 2016.
Conference Call and Webcast
Kura’s management will host a webcast and conference call regarding this announcement at
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Kura Oncology’s product candidates, tipifarnib, KO-947 and KO-539, progress and expected timing of Kura Oncology’s drug development programs and clinical trials, plans regarding regulatory filings and future research and clinical trials, the strength of Kura Oncology’s balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that
|KURA ONCOLOGY, INC.|
|Statements of Operations Data|
|(in thousands, except per share data)|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Research and development||$||7,142||$||5,316||$||18,307||$||14,901|
|General and administrative||2,357||1,742||6,775||5,988|
|Total operating expenses||9,499||7,058||25,082||20,889|
|Other income, net||166||132||396||676|
|Net loss per share, basic and diluted||$||(0.38||)||$||(0.37||)||$||(1.16||)||$||(1.09||)|
|Weighted average number of shares used in computing net loss per share, basic and diluted||24,344||18,850||21,217||18,549|
|KURA ONCOLOGY, INC.|
|Balance Sheet Data|
|September 30, 2017||December 31, 2016|
|Cash, cash equivalents and short-term investments||$||100,805||$||67,790|
|Total stockholders’ equity||89,199||56,876|
Vice President, Investor Relations & Corporate Communications
Westwicke Partners, LLC